- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01211717
The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients
April 21, 2011 updated by: Loma Linda University
The purpose of this study is to determine the effectiveness of the 3 Branched Chained Amino Acids (isoleucine, leucine, and valine) on treating Delayed Onset Muscle Soreness, a type of muscle pain which usually develops after exercising.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Delayed Onset Muscle Soreness is a common painful sensation experienced by individuals who have been recently inactive and begin with an unaccustomed exercise protocol.
Branched Chained Amino Acids have been found as a useful supplement for promoting muscle recovery following exercise; however the effects of this supplement have not been investigated amongst individuals with diabetes.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Loma Linda, California, United States, 92354
- Loma Linda University, School of Allied Health Professions
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subjects with diabetes must have been diagnosed with diabetes at least one year before the onset of the study
- At least 6 weeks of physical inactivity in the upper body
- BMI less than 40
Exclusion Criteria:
- For the Diabetics, hemoglobin A1c levels over 13
- Pregnant
- Have Cardiovascular diseases
- Have Hepatic diseases
- Are diagnosed with Rhabdomyolysis
- Recent upper limb injuries
- Upper limb neuropathy
- Blood Pressure levels over 140/90, or lower than 90/60
- Are on High doses of alpha or beta agonist/antagonists, and take any types of NSAID's, Cox 2 inhibitors, Calcium channel blockers, Pre-Gabalin's, or Pain reducers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Branched Chained Amino Acids
|
Two doses of the Branched Chained Amino Acid supplement will be taken.
The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise.
The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used.
This dose will be divided in half and administered at the two specified occasions.
The ratio of isoleucine, leucine, and valine will be 1:2.5:1
respectively
Other Names:
|
Placebo Comparator: Cellulose mix
|
The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise.
This dose will be divided in half and administered at the two specified occasions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measuring Pain, using the short form McGill pain questionnaire
Time Frame: 5 days following the initial exercise
|
5 days following the initial exercise
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measuring Muscle strength of the studied muscle
Time Frame: 5 days following the initial exercise
|
5 days following the initial exercise
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jerrold Petrofsky, Doctoral PhD, Loma Linda University, School of Allied Health Professions
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
September 28, 2010
First Submitted That Met QC Criteria
September 28, 2010
First Posted (Estimate)
September 29, 2010
Study Record Updates
Last Update Posted (Estimate)
April 22, 2011
Last Update Submitted That Met QC Criteria
April 21, 2011
Last Verified
April 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5100233
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Branched Chained Amino Acids
-
Szeged UniversityActive, not recruitingTonsil DiseaseHungary
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
University of Western Ontario, CanadaSuspended
-
University Hospital, GenevaCompleted
-
Montana State UniversityM.J. Murdoch Charitable Trust; Kreighbaum EndowmentCompleted
-
University of TorontoCompletedHealthy | Increased Metabolic Requirement
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedHepatic EncephalopathySpain
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Beth Israel Deaconess Medical CenterNational Institute of Mental Health (NIMH)Completed
-
Mahidol UniversityRecruitingDecompensated Cirrhosis and AscitesThailand